Xequel Bio is a biotechnology company working to revolutionize the way injuries heal. Our aCT1 platform has limitless potential to bring solutions to unmet needs in a variety of therapeutic areas. Current work is focused on multiple indications across dermatology, ophthalmology, and pulmonology. By addressing the underlying pathophysiology of inflammation and injury-based medical conditions, Xequel Bio’s technologies can provide physicians with new treatment options to improve patient outcomes.

Granexin® gel is our flagship product and is in late-stage clinical trials. Also in clinical trials is iNexin eye drops, and our inhalation solution is in advanced preclinical development. This pipeline of innovation demonstrates the variety of applications for the aCT1 platform, and Xequel Bio is dedicated to getting these to market to help those who could benefit from their use!